全文获取类型
收费全文 | 7601篇 |
免费 | 513篇 |
国内免费 | 131篇 |
专业分类
耳鼻咽喉 | 24篇 |
儿科学 | 344篇 |
妇产科学 | 65篇 |
基础医学 | 1456篇 |
口腔科学 | 19篇 |
临床医学 | 513篇 |
内科学 | 1110篇 |
皮肤病学 | 40篇 |
神经病学 | 974篇 |
特种医学 | 95篇 |
外科学 | 152篇 |
综合类 | 1208篇 |
预防医学 | 1456篇 |
眼科学 | 42篇 |
药学 | 463篇 |
中国医学 | 113篇 |
肿瘤学 | 171篇 |
出版年
2023年 | 93篇 |
2022年 | 166篇 |
2021年 | 307篇 |
2020年 | 318篇 |
2019年 | 201篇 |
2018年 | 214篇 |
2017年 | 200篇 |
2016年 | 245篇 |
2015年 | 268篇 |
2014年 | 454篇 |
2013年 | 473篇 |
2012年 | 443篇 |
2011年 | 555篇 |
2010年 | 442篇 |
2009年 | 400篇 |
2008年 | 351篇 |
2007年 | 383篇 |
2006年 | 345篇 |
2005年 | 320篇 |
2004年 | 251篇 |
2003年 | 247篇 |
2002年 | 173篇 |
2001年 | 128篇 |
2000年 | 154篇 |
1999年 | 125篇 |
1998年 | 96篇 |
1997年 | 77篇 |
1996年 | 75篇 |
1995年 | 66篇 |
1994年 | 85篇 |
1993年 | 47篇 |
1992年 | 52篇 |
1991年 | 48篇 |
1990年 | 43篇 |
1989年 | 37篇 |
1988年 | 45篇 |
1987年 | 24篇 |
1986年 | 20篇 |
1985年 | 44篇 |
1984年 | 41篇 |
1983年 | 25篇 |
1982年 | 29篇 |
1981年 | 15篇 |
1980年 | 16篇 |
1979年 | 13篇 |
1978年 | 13篇 |
1977年 | 11篇 |
1974年 | 8篇 |
1973年 | 14篇 |
1972年 | 7篇 |
排序方式: 共有8245条查询结果,搜索用时 31 毫秒
1.
《Vaccine》2022,40(19):2679-2695
Vaccinations are essential for preventing infectious diseases in children with chronic diseases as they have increased risk of infection from frequent use of biologics. Response to immunizations in this group is not well known.ObjectiveA systematic review was performed to evaluate three primary outcomes: efficacy; immunogenicity; and safety of vaccines in children with chronic conditions treated with biologics.MethodsThe protocol for our systematic review and meta-analysis was registered and published with PROSPERO. We searched electronic bibliographic databases for studies published from 2009 to 2019, focusing on vaccinations in children with chronic conditions treated with biologics.ResultsWe retrieved 532 records. Thirty-one full-text articles were selected, and 14 were included in the meta-analysis. No significant publication bias was found. Efficacy: limited data are available regarding the efficacy of vaccination, as most studies have focused on immunogenicity as surrogate outcome for efficacy. Immunogenicity: patients receiving anti-TNF-alpha therapy had a statistically significant risk of poor seroconversion (p = 0.028) and seroprotection by the serotype B influenza vaccine [inflammatory bowel disease (IBD) p = 0.013; juvenile idiopathic arthritis (JIA) p = 0.004]. We found adequate responses with H1N1 and H3N2 serotypes. Few studies existed for pneumococcal, hepatitis A virus, hepatitis B virus, varicella-zoster virus, Measles Mumps Rubella virus, and multiple vaccine administration. Safety: vaccine administration was not associated with serious side effects, but JIA patients on anti-TNF alpha therapy had a statistically significant risk of presenting with myalgia or arthralgia postinfluenza vaccine (p = 0.014).ConclusionsMore evidence concerning efficacy, immunogenicity, and safety of vaccinations is needed to guide physicians in the vaccine decision process for this pediatric population. 相似文献
2.
《Vaccine》2022,40(26):3490-3494
The current WHO Recommendations to assure the quality, safety and efficacy of live attenuated yellow fever vaccines were adopted in 2010. This document recommends that vaccine virus master and working seed lots should be tested for viscerotropism, immunogenicity and neurovirulence in monkeys. A vaccine manufacturer has reported, recently, discrepancies on the clinical scoring of monkeys during assessment of working seed lots and suggested aligning neurotropism assessment of yellow fever vaccines virus seed lots with that of neurovirulence testing of polio vaccines virus seed lots. In this approach, clinical signs are recorded but do not form part of the assessment or pass/fail criteria. At its 71st meeting in August 2020, the ECBS agreed to establish a drafting group and to consult with manufacturers and other stakeholders on the proposed amendment. Then a survey had been conducted to seek opinions of stakeholders on the neurotropism testing and revision of current WHO Recommendations for yellow fever vaccines. It was recognized from the answers of the survey that the test for neurovirulence in monkeys presents several technical challenges which could be addressed in the amended version of the Recommendations.On 18–19 March 2021, a virtual WHO working group meeting was held to discuss a proposed draft of the amended text with participants of yellow fever vaccine manufacturers and relevant regulators. Overall, there was a consensus among manufacturers and regulators that clinical evaluation provides important information and should be retained as part of the neurotropism test. However, there was also agreement that the test is somewhat subjective, and that analysis can be difficult. It was recognized that there was potential for improvement in both test execution and analysis to increase harmonization between manufacturers. Alternative tests to the non-human primates neurovirulence test would be useful but it was agreed that none seem to be sufficiently developed at present. Based on these working group discussions, it was proposed that the appendix on neurotropism test to be further revised by the WHO drafting group and submitted to ECBS for review and adoption.Issues other than neurotropism test were discussed in the meeting as well. There were a number of points identified during the meeting, such as new platform of production, animal models, deep sequencing, international standards, that are outside the current recommendations that are worthy of further discussion. Therefore, it is recommended that there would be a future meeting with various stakeholders to discuss the potential revision of the whole Recommendations for yellow fever vaccines in order to meet the current needs. 相似文献
3.
背景:儿童新型冠状(新冠)病毒Omicron变异株流行期间,免疫抑制状态儿童新冠病毒清除时间定量分析研究较少。
目的:探讨新冠病毒Omicron株感染后免疫抑制和非免疫抑制儿童病毒清除的时间差别,为公共卫生政策制定和精准疫情防控措施提供临床数据。
设计:回顾性队列研究。
方法:以新冠病毒Omicron变异株感染住院患儿为队列人群,分为免疫抑制组和非免疫抑制组,免疫抑制分为绝对免疫抑制、相对免疫抑制和实施免疫抑制疗法,以免疫抑制组病例的性别、年龄和新冠病毒感染的分型与非免疫抑制组行1∶3匹配。以鼻咽拭子新冠病毒PCR检测拷贝数阈(Ct)值≥35为队列终点。
主要结局指标:新冠病毒清除时间。
结果:2022年4月12日至2022年5月12日在上海市新冠病毒感染定点收治医院符合本文共同纳入和排除标准的连续病例728例。免疫抑制组33例,其中绝对免疫抑制8例,相对免疫抑制23例,接受免疫抑制疗法2例(不包括绝对和相对免疫抑制患儿)。非免疫抑制组匹配后99例。2组临床症状、新冠病毒感染治疗和疫苗接种次数差异均无统计学意义。免疫抑制组和非免疫抑制组新冠病毒清除时间分别为(16.5±6.8)和(10.3±4.4)d,差异有统计学意义。免疫抑制组和非免疫抑制组新冠病毒感染轻型病例病毒清除时间分别为(14.0 ± 8.3)和(9.7 ± 3.1)d,普通型病例病毒清除时间分别为(18.3 ± 4.9)和(11.2 ± 5.9)d,差异均有统计学意义。2组单日病毒清除率在第9~14天时差异有统计学意义(P为0.005~0.039)。2组普通型病例单日病毒清除率在第10~15天时差异有统计学意义。免疫抑制组新冠病毒感染2周后核酸检测再次呈阳性3例(9%),临床分型均较前轻,3例均未接种新冠疫苗。
结论:Omicron株感染的免疫抑制患儿病毒清除时间较非免疫抑制患儿显著延长,主要反映在第9~14天,免疫抑制患儿病毒复阳风险高,提示需要更长的隔离时间和转阴后严格的病毒监测。 相似文献
4.
5.
6.
姚峰 《中国工业医学杂志》2022,35(2):191-191